FDA-Approved Biomarker Panels: The Good, The Bad, and The Ugly

Here at Amplion we are currently thinking very hard about how to represent in BiomarkerBase the ways in which emerging biomarkers are naturally grouping into panels, based on how they are used in clinical trials, described in the literature, and appear in clinical...

“As I lay dying” – A Powerful Personal Exhortation

This moving opinion piece in the LA Times was just shared with me by Adam Carroll (our CSO and co-founder), which was written by a distinguished foreign correspondent, Laurie Becklund, who just died of breast cancer. In this piece Laurie lays a withering blow on...

Linking Data Silos is a Major Key to Clinical Genomics

Part of President Obama’s “precision medicine” initiative is the characterization of the genomes of one million American volunteers. The proposal includes characterizing several hundred thousand new participants, and connecting the data with genetic...

Breast Cancer Tests Betray ‘Precision Medicine’ Branding

Yes, President Obama’s new $215 million Precision Medicine Initiative supports important science, but it also bolsters biotech branding in a way the science doesn’t always support. To understand why clinical genomics (a more neutral descriptor) isn’t quite as reliably...

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access